Skip to main content
. Author manuscript; available in PMC: 2014 Apr 22.
Published in final edited form as: J Clin Neurosci. 2013 Apr 29;20(6):818–823. doi: 10.1016/j.jocn.2012.07.016

Fig. 3.

Fig. 3

Survival for patients with poor preoperative Karnofsky Performance Scale scores stratified by independent predictors of outcome. (A) Survival by age. Patients older than 65 years had a median survival of 3.9 months as compared to 7.6 months for patients younger than 65 years (p = 0.02). (B) Survival by extent of resection. Patients who underwent subtotal resection (STR) had a median survival of 4.3 months as compared to 7.3 months for patients who had radical resection (p = 0.05). (C) Survival by tumor size. Patients who had tumors <2 cm in size had a median survival of 3.1 months as compared to 7.6 months for patients with larger tumors (p = 0.006). (D) Survival by temozolomide therapy. Patients who did not receive temozolomide had a median survival of 5.1 months as compared to 12.9 months for patients who received adjuvant therapy (p = 0.002).